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a  b  s  t  r  a  c  t
In this  review,  we  provide  an  overview  of  the  clinical  aspects,  histopathology,  molecular  genetics,  and
treatment  options  for Vulvar  Paget’s  Disease  (VPD),  a  rare skin  disease,  most  commonly  found  in  post-
menopausal  Caucasian  women.  The  underlying  cause  of VPD  remains  not  well  understood.  VPD  is  rarely
associated  with  an  underlying  urogenital,  gastrointestinal  or vulvar  carcinoma.  In  approximately  25% of
the cases,  VPD  is  invasive;  in  these  cases,  the prognosis  is worse  than  in  non-invasive  cases.  Recurrence
rates  in invasive  VPD  are high:  33% in  cases  with  clear  margins,  and even  higher  when  surgical  margins  are
not clear,  regardless  of invasion.  Historically,  surgical  excision  has  been  the treatment  of  choice. Recent
studies  show  that  imiquimod  cream  may  be an effective  and  safe  alternative.
© 2016  The  Authors.  Published  by  Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
. Introduction
Sir James Paget (1814–1899) was a surgeon with a special inter-
st in pathology and physiology. In addition to his work as a surgeon
or the English royal family and his practice in London, he wrote
Lectures on Surgical Pathology’, a work that established him as
ne of the founders of modern pathology along with Rudolf Vir-
how (Paget, 1853). Sir James Paget is best known for his paper
escribing a nipple ulceration that was associated with an under-
ying breast carcinoma (Paget, 1874). That paper reported a series
f 15 cases of chronic skin eruption of the nipple and areola, a con-
ition that is now referred to as mammary Paget disease. In 1889,
hortly after James Paget’s report, Crocker described the ﬁrst case of
aget disease on extramammary skin, a case involving penoscrotal
aget disease (Crocker, 1889). In 1901, Paget disease of the vulva
as described for the ﬁrst time by a French dermatologist, William
ubreuilh (Dubreuilh, 1901). Mammary and extramammary Paget
isease are characterized by the presence of intraepithelial mucin-
roducing neoplastic cells known as Paget cells. However, the exact
rigin of these cells remains unclear (Demopoulos, 1971). This
eview presents an overview of the current literature on invasive
nd non-invasive VPD, including its epidemiology, clinical aspects,
istopathology, treatment options, and survival.
. Methods
.1. Data sources
Relevant publications were identiﬁed by a computer search in
he PubMed database (date of last search April 9th, 2015). We
earched the database using combinations of the following terms:
Paget’s disease’, ‘Paget disease, extramammary’ or ‘Paget’ in title
nd text. Subsequently, these terms were combined with ‘vulva’,
vulvar’, ‘vulval’, ‘genitalia’, ‘perianal’ or ‘anogenital’. The button
related articles’ in PubMed and reference lists from selected arti-
les were used to identify additional papers. Also, gynaecologic
ncology, pathology and dermatology handbooks were used. Over-
ll, 852 studies were found, 324 studies were not available in
ull-text and after assessment of all titles and abstracts, 298 were
onsidered relevant. Main reasons for exclusion were: extramam-
ary Paget disease in males, or locations other than the vulva. The
emaining publications on VPD were considered for inclusion in
his review if they reported one of the topics mentioned in this
eview. Of these 298 studies 230 reported clinical or histopatholog-
cal data of patients with VPD, including 79 case-reports and 53 case
male and female patients with EMPD were considered for inclu-
sion. However, we  only used data of female patients with EMPD
located on the (ano) genital skin, unless there was  no data on VPD
available.
2.2. Terminology
In this review, the terms mammary Paget disease (MPD) will
be used for Paget disease of the breast, and extramammary Paget
disease (EMPD) will be used for other locations, including the
anogenital skin in males. The term vulvar Paget disease (VPD) will
be used for a disease location in the genital area in females, includ-
ing the perineal and perianal skin.
3. Clinical characteristics
3.1. Epidemiology
Only one study presents the occurrence of MPD  versus EMPD:
90% of all cases of Paget disease are MPD  and 10% of all cases of Paget
disease are EMPD (Fardal et al., 1964). The overall European inci-
dence of EMPD is 0.7 per 100,000 persons per year, and is slightly
higher for women than men. A study in 16 European countries
reported 871 cases of invasive EMPD in 13 years, including 231
male and 640 female patients (van der Zwan et al., 2012). Of the
640 female patients, disease was  located at the vulva in 533 patients
(83%), 3 cases were reported as ‘Paget disease of the female genital
tract, not otherwise speciﬁed’ (0.5%), and 21 cases were reported
as ‘Paget disease of the anal canal and perianal skin’ (3%). VPD is
reported to occur most often in postmenopausal Caucasian women.
In the Asian population, EMPD is seen mostly in males (Chiu et al.,
2007), but there is considerable literature describing VPD in Asian
women (Hatta, 2006; Takahashi and Yamamoto, 2004; Wang et al.,
2004; Xiong et al., 2004; Lee et al., 2009; Liu et al., 2014). However,
the exact incidence of VPD is unknown.
EMPD may  be associated with underlying vulvar adenocarci-
noma. Invasive VPD represents 1–2% of all vulvar carcinomas (Lloyd
and Flanagan, 2000). A Dutch epidemiology study including 226
cases of EMPD over a 13-year period found that 178 (79%) cases
were invasive and 48 (21%) non-invasive. When the data were
categorised by location, invasive VPD (n = 59) was reported twice
as often as non-invasive VPD (n = 32) (Siesling et al., 2007). These
data were taken from the Netherlands Cancer Registry, which may
have resulted in underreporting of non-invasive disease. Most clin-eries with <10 patients. We  prepared tables of clinical data based
n studies that included 10 patients or more, to ensure the size
f the tables remained manageable. Studies that reported on bothical studies used Wilkinson’s classiﬁcation, and report invasion in
16–19% of the cases, and a vulvar adenocarcinoma in 4–17% of all
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excised. The diagnosis is conﬁrmed by the histological presence of
Paget cells.2 M. van der Linden et al. / Critical Review
ases (Niikura et al., 2006; Mendivil et al., 2012; Karam and Dorigo,
014). Moreover, VPD might not be recognized and thus be under-
eported if no skin biopsy is performed to conﬁrm the diagnosis.
.2. Origin of extramammary Paget disease
The origin of EMPD has not been clariﬁed, although there are
urrently three theories. The ﬁrst suggests that EMPD has an
ntraepidermal origin from adnexal structures, like apocrine glands,
ultipotent stem cells in the epidermal basal layer or infundibular
tem cells of the hair follicle (Lloyd and Flanagan, 2000; Kanitakis,
007; Regauer, 2006). EMPD is typically located in the hair-bearing
kin of the axilla or genital area which supports the disease ori-
ins from adnexal structures. Although, VPD can also occur in the
odiﬁed mucosa of the interlabial sulcus, or, in advanced cases,
n the glycogenated mucosa without adnexal structures (Abbott
nd Ahmed, 2006; Lloyd et al., 1999; Mahdi et al., 2011), which
upports another theory suggesting that Paget cells originate from
ammary-like glands, which are located in the interlabial sulci
van der Putte, 1994). A more recent theory is that Toker cells are
recursor cells in MPD  as well as in EMPD and VPD (Willman et al.,
005; Toker, 1970). Toker cells have a single round nucleus and pale
ytoplasm and are usually found in the nipple and areola (Belousova
t al., 2006; Hashemi et al., 2014).
.3. Signs and symptoms
In the majority of patients, VPD causes symptoms such as irri-
ation, itching, and burning. VPD can be asymptomatic in some
atients: about 5–15% of patients have no symptoms at the time
f diagnosis (Perez et al., 2014; De Magnis et al., 2013). Upon phys-
cal examination, VPD presents as an erythematous plaque with
ypical white scaling known as “cake-icing scaling”. It is a clinical
hameleon as it can present with a variety of colours and macu-
ar or plaque-like presentation. The plaque may  be ulcerated and
rusted with a papillomatous surface, as shown in Figs. 1 and 2. The
ymptoms experienced by the patient are not always related to the
xtent of the visible lesion.
Studies have shown that symptoms are typically present for an
verage of almost 2 years before the diagnosis is made, due to both
atient and doctor delays (De Magnis et al., 2013; Chanda, 1985;
ig. 1. Peri-anal Paget disease. Poorly demarcerated erythematous perianal plaque
ith small erosions and white scaling.ncology/Hematology 101 (2016) 60–74
Fanning et al., 1999). There is limited knowledge regarding the nat-
ural course of VPD, as most study reports describe patients who
have undergone surgery. The ‘Radiumhemmet series’ of 28 women
describes 4 patients with untreated VPD. Of these four women, two
women were inoperable and two women  refused surgery. Both
inoperable patients died of other causes. One of the two women
who refused surgery died of a squamous cell carcinoma (SCC) of
the vagina, and the other patient had progressive VPD (Baehrendtz
et al., 1994).
3.4. Diagnosis
In cases of suspected VPD, an accurate medical history should be
taken, including a history of vulvovaginal complaints and gastroin-
testinal and urological symptoms. In addition, a full gynaecological
examination should be performed that includes vulvar, vaginal,
and rectal examinations. All raised, pigmented, or otherwise sus-
picious lesions should be addressed appropriately by a thorough
report, digital photography, and histological examination. Digital
photographs can help monitoring the course of the disease. Inva-
sive disease should be excluded, preferably by vulvar mapping,
including multiple biopsies of the involved and surrounding unin-
volved skin. In case of a small unifocal lesion, it can be considered
to perform a single biopsy, in which the visible lesion is completelyFig. 2. Vulvar Paget disease. White hyperkeratotic plaque with typical ‘cake-icing’
scaling with small superﬁcial erosions on the right labium majus.
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prolonged follow-up in a multidisciplinary vulvar clinic or by
a gynaecological oncologist” (Royal College of Obstetricians &
Gynaecologists, 2014). The U.S. Department of Health & HumanM. van der Linden et al. / Critical Review
.5. Differential diagnosis
In addition to eczema and vulvovaginal candidiasis, the dif-
erential diagnosis of VPD consists of psoriasis, lichen simplex
hronicus, lichen sclerosus, lichen planus, differentiated vulvar
ntraepithelial neoplasia (VIN) or usual VIN (synonymous: high
rade squamous intraepithelial lesion, or H-SIL), SCC, histiocytosis,
ondylomata acuminata and melanoma. In addition to these clini-
al diagnoses, a histological differential diagnosis of intraepithelial
agetoid cells can include the following: melanoma (in situ), page-
oid spitz naevus, sebaceous carcinoma, clear cell papulosis, eccrine
orocarcinoma, cutaneous T-cell lymphoma, and Langerhans cell
icroabscess (Fanning et al., 1999; Shepherd et al., 2005; Delport,
013).
.6. Classiﬁcation
The World Health Organization (WHO) deﬁnes VPD as ‘an
ntraepithelial neoplasm of epithelial origin expressing apocrine
r eccrine glandular-like features and characterized by distinctive
arge cells with prominent cytoplasm, referred to as Paget cells’
Crum et al., 2014). In the International Society for the Study of Vul-
ovaginal Disease (ISSVD) Terminology and Classiﬁcation of Vulvar
ermatologic Disorders (2011), VPD is assigned to the morpholog-
cal group 2, described as ‘Red lesions, patches and plaques’ and
o subgroup B, ‘Red patches and plaques (no epithelial disruption)’
Lynch et al., 2012).
In 2001, Wilkinson et al. proposed a histopathological classiﬁ-
ation of VPD that distinguishes primary/cutaneous VPD (type 1)
rom secondary/non-cutaneous VPD (Wilkinson and Brown, 2002;
ilkinson, 2002). As shown in Table 1, secondary VPD originates
rom a malignancy of the gastrointestinal tract (type 2) or the uro-
enital tract (type 3) (Nowak et al., 1998). In cases of pagetoid
xtension of an urothelial carcinoma, the term pagetoid urothelial
ntraepithelial neoplasia (PUIN) may  be used. The current literature
ften refers to Wilkinson’s classiﬁcation, which is mainly based on
he histopathologic features of VPD. However, this classiﬁcation
s no longer supported by the most recent WHO  Classiﬁcation of
umours of Female Reproductive Organs (4th edition) (Crum et al.,
014). Moreover, it is a matter of debate whether non-cutaneous
MPD should be regarded as a form of VPD. Some consider it a direct
xtension (‘pagetoid spread’) of an intestinal or urothelial malig-
ancy and use immunohistochemistry to distinguish primary from
econdary VPD (see Section 4.2) (Crum, 2011). There are no accu-
ate data regarding the distribution of types 2 and 3 versus type
 VPD. Together with Wilkinson’s classiﬁcation, the subdivision of
utaneous and non-cutaneous EMPD is regularly used in current
iterature.
Cutaneous VPD (type 1) is further subdivided according to the
resence or absence of dermal invasion: type 1a (intraepithelial dis-
ase), is reported to account for 75–81% of all primary VPD cases,
ype 1b in 16–19% and type 1c in 4–17% of all cases (Niikura et al.,
006; Mendivil et al., 2012; Karam and Dorigo, 2014). In contrast,
0% or more of patients with MPD  have an underlying breast malig-
ancy (Chaudary et al., 1986). It is hypothesized that Paget cells
igrate from the epidermis to the dermis in type 1b and that in
ype 1c the Paget cells have migrated into the epidermis (“pagetoid
pread”) from an underlying vulvar adenocarcinoma.
Most studies do not report the deﬁnition of ‘invasive VPD’ or
vulvar adenocarcinoma’ that was used. Some described dermal
nvasion as ‘invasion > 1 mm’.  Curtin et al. deﬁned vulvar adenocar-
inoma as invasive adenocarcinoma of sweat gland origin (Curtin
t al., 1990). Lee et al. deﬁned invasive VPD as Paget disease with
n situ involvement of the underlying sweat glands and deﬁned
ulvar adenocarcinoma as an invasive adnexal adenocarcinoma
Lee et al., 1977). Because most studies lack clear deﬁnitions ofncology/Hematology 101 (2016) 60–74 63
invasive VPD and vulvar adenocarcinoma, we  are unable to present
an overview of the incidence distribution of non-invasive VPD,
invasive VPD, and VPD with an underlying adenocarcinoma.
3.7. Associated malignancies
Patients diagnosed with EMPD are reported to have a higher
risk of developing a second primary cancer, especially the ﬁrst
year after diagnosis (standardized incidence ratio of 1.39 with a
95% CI of 1.11–1.73) (van der Zwan et al., 2012). VPD is reported
to be associated with other malignancies in 11–54% of the cases,
including malignancies of the breast, vagina, cervix, uterus, ovary,
gallbladder, and liver (Karam and Dorigo, 2014; Lee et al., 1977;
Feuer et al., 1990; Taylor et al., 1975). However, some studies con-
sider an underlying vulvar, rectal, or urothelial carcinoma to be an
associated malignancy, whereas others reserve this term for distant
malignancies. Data need to be interpreted with caution, since most
studies reporting on associated malignancies had no adequate age
matched control groups.
A total of 15 studies with 10 or more patients, reported intestinal
or urological malignancies in patients with VPD (Liu et al., 2014; De
Magnis et al., 2013; Baehrendtz et al., 1994; Brown and Wilkinson,
2002; Crawford et al., 1999; Helm et al., 1992; Jones et al., 2011;
Pierie et al., 2003; Tebes et al., 2002; Lundquist et al., 1999; Black
et al., 2007; Lee et al., 2011; Luyten et al., 2014; Plaza et al., 2009;
Press et al., 2011). Of the 456 included patients 10 (2.2%) had intesti-
nal malignancies, and 18 (3.9%) had urological malignancies. Five
patients were reported to have VPD and a simultaneous bladder
carcinoma (1.1%) and 3 patients (0.7%) had an anal carcinoma that
occurred simultaneously with VPD (Brown and Wilkinson, 2002;
Pierie et al., 2003; Lundquist et al., 1999; Press et al., 2011). Twenty-
six studies with 10 patients or more reported that 51 (3.2%) of the
included 1598 patients had a history of breast cancer (Liu et al.,
2014; Niikura et al., 2006; Mendivil et al., 2012; Karam and Dorigo,
2014; De Magnis et al., 2013; Fanning et al., 1999; Baehrendtz
et al., 1994; Lee et al., 1977, 2011; Feuer et al., 1990; Taylor et al.,
1975; Crawford et al., 1999; Helm et al., 1992; Jones et al., 2011;
Pierie et al., 2003; Tebes et al., 2002; Black et al., 2007; Plaza et al.,
2009; Press et al., 2011; Brainard and Hart, 2000; Cai et al., 2013;
Goldblum and Hart, 1997; Gregori et al., 1978; Kodama et al., 1995;
Parker et al., 2000; Zollo and Zeitouni, 2000). The time relative to
the diagnosis of VPD varied greatly. Based on currently available lit-
erature it is not proven that there is a clinical relationship between
VPD and breast cancer.
3.8. Excluding other malignancies
There is no current consensus if women with VPD should
be screened for associated malignancies, or which additional
tests should be performed. Because of the presumed association
of VPD with locoregional and distant malignancies, guidelines
advise excluding the presence of other malignancies, although
the proposed policies vary. The Royal College of Obstetricians and
Gynaecologists states that “the gastrointestinal and urinary tracts
and the breasts should be checked” (Royal College of Obstetricians
& Gynaecologists, 2011) and that “women with VPD should haveServices advises, “evaluate the breasts, genitourinary, and gastroin-
testinal tract (level C evidence: consensus and expert opinion)”
(ACOG National Guideline, 2008).
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Table 1
Classiﬁcation of vulvar Paget disease by Wilkinson (Delport, 2013; Crum et al., 2014).
Primary VPD (cutaneous) Type 1a Cutaneous vulvar non-invasive Paget’s disease
Type 1b Cutaneous vulvar invasive disease: dermal invasion of Paget cells
Type 1c Cutaneous vulvar disease as a manifestation of an underlying vulvar adenocarcinoma
Secondary VPD (non-cutaneous) Type 2 VPD originates from rectal or anal adenocarcinoma
Type 3 VPD 
Fig. 3. Non-invasive vulvar Paget disease (HE stain, 100x). Solitary cells and large
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whereas CK20, CDX2, and MUC2 positivity might indicate an under-
F
hell nests are present in the lower parts of the epidermis (arrows). The Paget cells
ave pale cytoplasm and large rounded atypical nuclei. There is no invasive growth.
. Histopathological diagnosis
.1. Histological characteristics
Histologically, VPD is characterized by the presence of large
val or polyhedral intraepithelial cells that have pale cytoplasm
nd large nuclei with prominent nucleoli, these cells are the so-
alled Paget cells. Paget cells can be visualised using haematoxylin
nd eosin (HE) staining. They are arranged either singly or in clus-
ers throughout the epithelium to a variable extent, and may  form
 lumen or gland-like structures. Sometimes reactive changes are
een in the surrounding epithelial surface, such as acanthosis, papil-
omatosis, and hyperkeratosis; these changes in themselves are not
ufﬁcient for diagnosis. A lichenoid inﬂammatory inﬁltrate can be
een in the underlying papillary dermis. The scattered Paget cells
re diagnostic, but they are interspersed within the normal epithe-
ium and can be difﬁcult to detect at times (Figs. 3 and 4).
ig. 4. (A) Non-invasive vulvar Paget disease (HE, 100x), (B) Cytokeratin 7 stained cells (
yperplastic epidermis. With CK7 it is clearly depicted that there is no invasive growth inoriginates from urogenital neoplasia
In the pathologic assessment of VPD, it is important to
exclude invasive growth. This is challenging because it is not
uncommon for VPD to extend into the adnexal structures. An addi-
tional problem is the frequent presence of a dense inﬁltrate that can
obscure the epithelial/stromal interface. Invasion is characterized
by the presence of dyscohesive neoplastic Paget cells inﬁltrating
the underlying dermis or submucosa (Figs. 5 and 6). In case of inva-
sion, the pathologist is required to report the depth of invasion, as
this has proven prognostic signiﬁcance and determines the type of
treatment (Hatta et al., 2008; Ito et al., 2012).
4.2. Immunohistochemistry
A number of immunohistochemical stains can be used to distin-
guish cutaneous VPD from its histological mimics. Paget cells can be
highlighted by PAS reaction and/or by immunohistochemistry, as
they are usually positive for cytokeratin (CK) 7 and carcinoembry-
onic antigen (CEA) (Delport, 2013; Berek and Hacker, 2005; Kuan
et al., 2001). They do not express markers of squamous cell differ-
entiation, such as p63 and p40, and these markers can therefore be
used to exclude squamous intraepithelial lesions such as uVIN, also
known as HPV-induced H-SIL with a pagetoid growth (Yanai et al.,
2008; Hoang et al., 2015). However, VPD may  over express p16 and
mimic  uVIN (or: HPV-induced H-SIL), which strongly over express
p16 as well (McCluggage et al., 2009; Sah and McCluggage, 2013).
In addition, Paget cells do not express melanocyte markers, such
as Mel-A, HMB45 or S100, and this can help distinguish VPD from
(in situ) melanoma. Paget cells may  express androgen receptors,
but in general are negative for estrogen and progesterone recep-
tors (Olson et al., 1991; Liegl et al., 2005; Diaz de Leon et al., 2000;
Horn et al., 2008).
Immunohistochemistry can also be helpful in determining the
primary location of an underlying adenocarcinoma. For exam-
ple, pagetoid extension of urothelial cancer will likely express
CK20, uroplakin-III, and GATA-3 (Delport, 2013; Horn et al., 2008),lying anorectal adenocarcinoma (Delport, 2013; Kuan et al., 2001;
Liao et al., 2014). It is therefore recommended that a combination of
these markers be used in cases in which pagetoid extension from an
100x). Large pale solitary cells and cell nests are present throughout the thickened
 the underlying vulvar stroma.
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Fig. 5. (A) Micro-invasive vulvar Paget disease (HE, 100x), (B) Detail (HE, 200x). Some large atypical pale cells and cell nests are present in the basal layers of the vulvar
epithelium. At magniﬁcation it is shown that two smell cell clusters have invaded the underlying vulvar stroma (arrows). The invasive growth is less than 1 mm.
Fig. 6. (A) Invasive Paget disease with underlying anogenital invasive adenocarcinoma (HE, 100x), (B) Cytokeratin 7 stained cells (100x). At left a poorly differentiated
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e such as regulatory T-cells (Tregs) that suppress effector T-cells.
Tregs express Foxp3, CD4, and CD25 (or Il-2-R), and high numbers
T
O
Cdenocarcinoma is present directly under the hyperplastic thickened vulvar epithel
he  basal parts and rete ridges of the vulvar epithelium.
nderlying adenocarcinoma is suspected (Ohnishi and Watanabe,
000). Because of the rarity of a co-existent intestinal and/or uro-
ogical (see Section 3.7) we suggest this may  be performed in cases
n which the patient has a clinical suspicion of an underlying intesti-
al and/or urological tumour. See Table 2 for an overview of the
xpression patterns of common markers.able 2
verview of common expression patterns in vulvar Paget disease.
CEA p63 CK 7 C
Primary cutaneous VPD (type 1) + – + – 
Secondary to intestinal malignancy (type 2) + – – + 
Secondary to urological malignancy (type 3) + + +/− + 
EA: carcinoembryonic antigen, CK: cytokeratin, Uro-III: uroplakin-III, MUC2: mucin 2, Gith cytokeratin 7 immunostaining it is depicted that tumour cells spread alongside
4.3. Tumour microenvironment
Studies of the local tumour microenvironment of VPD are lim-
ited and have not investigated the types of cells present in the
immune inﬁltrate, only speciﬁc markers have been investigated,of Tregs are associated with adverse clinical outcomes in several
types of cancer (Fujimura et al., 2012; Adeegbe and Nishikawa,
K 20 Uro-III GATA-3 CDX2 MUC2 GCDFP-15
– – – – +
– – + + –
+ + – – –
CDFP-15: Gross cystic disease ﬂuid protein.
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013; Piersma et al., 2007). A study of Tregs in 44 cases of VPD
howed that Tregs are frequently found at the epidermal-dermal
unction (Press et al., 2011) whereas the surrounding healthy skin is
egative for Tregs. That study also described a correlation between
he number of FOXP3+ Tregs and positive surgical margins and
ecurrence (Press et al., 2011). The percentage of Tregs is signiﬁ-
antly higher in non-invasive EMPD than in invasive EMPD, while
D163+ macrophages are detected more frequently in invasive
MPD (Fujimura et al., 2012).
.4. Genetic proﬁle
Given the rarity of VPD, there are limited data on genetic
lterations in VPD, and this ﬁeld is therefore largely unexplored.
er2/Neu ampliﬁcation is probably the most studied genetic alter-
tion in VPD, likely because of its therapeutic potential and its
ssociation with mammary Paget disease. HER-2/Neu overexpres-
ion is found in 70–100% of MPD  cases (Wolber et al., 1991;
eatings et al., 1990). However, the reported frequency of Her2/Neu
mpliﬁcation in EMPD varies signiﬁcantly (Bianco and Vasef, 2006;
eich et al., 2005). Small series and case reports have inves-
igated various genetic abnormalities: mutations in the PIK3CA
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Sub-
nit Alpha) gene, divergent DLC1 (Deleted in Liver Cancer 1)
ethylation, single nuclear polymorphism in the XRCC1 (X-ray
epair cross-complementing protein 1) gene, chromosome 7 gains
nd X chromosome losses have been described (Kang et al., 2012;
hiyomaru et al., 2012; Micci et al., 2003). However, the clinical
igniﬁcance of these abnormalities remains to be determined.
. Treatment
Traditionally, the treatment of choice for VPD is surgical exci-
ion.
.1. Surgery
Surgical treatment of VPD consists mainly of wide local exci-
ion, with or without inguinofemoral lymph node dissection (De
agnis et al., 2013; Fanning et al., 1999; Edey et al., 2013). A
nguinofemoral lymphadenectomy is indicated in cases showing
nvasive VPD (>1 mm).  The main clinical challenge of wide local
xcision is obtaining clear surgical margins; it is unclear what
he surgical margin should be in VPD, as Paget disease spreads
icroscopically throughout the epidermis. This makes it difﬁcult
o determine the complete extent and spread of the lesion (Gunn
nd Gallager, 1980). Paget cells may  be difﬁcult to recognize on
rozen sections: frozen section evaluation in EMPD is reported to
ave a false negative rate ranging from 10.4% to 13.2% (Chan et al.,
012; Zhu et al., 2007). The relationship between surgical margin
tatus and recurrence rates remains unclear (see Section 5.3).
In Mohs microsurgery (MMS)  the vulvar lesion is excised
hrough the epidermis and dermis, and 100% of the peripheral
argins are examined immediately (Mohs and Blanchard, 1979).
xcision is repeated, enlarging the circumference each time, until
he margins are clear. MMS  was reported to be used for VPD for the
rst time in 1991 (Coldiron et al., 1991), after 90 years of surgical
reatment consisting of wide local excision or (hemi) vulvectomy.
For large lesions, different plastic surgery methods for recon-
truction of large vulvovaginal defects have been reported and
nclude local fasciocutaneous ﬂaps, gluteal fold ﬂaps, pudendal
high ﬂaps, and gracilis myocutaneous ﬂaps (Araki et al., 2003;
akamura et al., 2010; Staiano et al., 2009; Yun et al., 2010).ncology/Hematology 101 (2016) 60–74
5.1.1. Sentinel lymph node
There are no studies on the accuracy of sentinel lymph node
(SLN) biopsies in invasive VPD. The current literature describes
SLN only sporadically in cases with microinvasive VPD (Ewing
et al., 2004) and in cases with suspected lymph node metastases
(Nakamura et al., 2012; Hatta et al., 2004). However, based on cur-
rent knowledge of surgery for vulvar SCC, microinvasion is not
an indication for SLN, and uni- or bilateral inguinofemoral lym-
phadenectomy is indicated in cases of invasive VPD (> 1 mm)  with
clinically suspected lymph node involvement.
5.1.2. Complications of surgery
Vulvar surgery is associated with signiﬁcant morbidity. Local
vulvar complications consist mainly of infection, hematomas, and
wound breakdown, with incidence rates for wound breakdown
ranging from 9–45% (Gaarenstroom et al., 2003; Senn et al., 2010;
Robison et al., 2014). According to quality of life assessments,
extensive surgery, such as radical vulvectomy, tends to cause
more discomfort than wide local excision (Gunther et al., 2014).
The incidence of complications after inguinofemoral lymphadenec-
tomy ranges from 17.5–84%. Early complications (<1 month after
surgery) are mainly lymphocyst formation, wound breakdown,
and infection of the wound. Late complications (≥1 month after
surgery) include lymphedema, leg pain, and erysipelas (Robison
et al., 2014; Hinten et al., 2011; Iversen et al., 1980; Walker et al.,
2011).
5.1.3. Psychosexual complications
There are no studies concerning the psychosexual effects of vul-
var surgery in VPD. One study showed that women with a history of
vulvar excision for VIN more frequently reported sexual function
impairment and worse quality of life than healthy women (Likes
et al., 2007). However, two  other studies showed no signiﬁcant
differences in quality of life and sexual function between patients
surgically treated for VIN, Bowen’s disease, or VPD and a healthy
population (Lavoue et al., 2013; Conklin et al., 2009). In patients
who underwent vulvar surgery for vulvar carcinoma or carcinoma
in situ, there was no correlation between the extent of the surgery,
the type of vulvectomy, and sexual dysfunction severity. Elderly
women were more likely to stop sexual activity after such surgery,
and women with high depression scores more often had sexual
aversion disorder, increases in body image disturbance, and sex-
ual dysfunction (Green et al., 2000). Following vulvar surgery for
VIN, older women had lower quality of life and lower sexual func-
tion according to the Female Sexual Function Index questionnaire
compared to younger women  (Likes et al., 2007).
5.2. Non-surgical treatment
Surgery for VPD is not always possible or desirable due to the
location or size of the lesion or due to patient factors or preferences.
In addition, recurrence rates after surgical treatment are high and
morbidity is impressive (Perez et al., 2014; Fanning et al., 1999).
There is thus a pressing need for alternative treatment options for
VPD.
5.2.1. Topical imiquimod cream
Imiquimod is registered for the treatment of condylomata
acuminata, superﬁcial BCCs, and actinic keratosis. It has also shown
to be effective in the off label treatment of usual VIN in ran-
domized controlled trials (van Seters et al., 2008; Tristram et al.,
2014). Imiquimod, a toll-like receptor (TLR) 7 agonist, is an immune
response modiﬁer. It triggers immune cells to produce cytokines,
including interferon-, interleukin 1, 6, and 8, and TNF- (Miller
et al., 1999). It also indirectly stimulates the production of pro-
inﬂammatory T helper type 1 cytokines. In the skin, imiquimod
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1 patient with invasive VPD (Son et al., 2005). All 3 patients had a
clinical complete response. Karam et al. performed a large retro-
spective study of 1439 patients with EMPD, 781 of whom had VPD.Fig. 7. Extended vulvar Paget disease before (A), after 4 weeks (B)
ctivates Langerhans cells, which enhance antigen presentation to
 cells.
A few observational studies and case reports have shown
miquimod to be effective for the treatment of perineal, scrotal, and
nguinal Paget disease (Zampogna et al., 2002). Topical imiquimod
ream for the treatment of recurrent VPD was ﬁrst described by
ang et al. (2003), and subsequently around 25 retrospective case
eries were published on the use of topical imiquimod cream in
on-invasive VPD. The treatment schedules differed widely in these
tudies, ranging from daily application to application three times
 week. The duration of the treatment ranged from 5 to 26 weeks,
nd follow-up ranged from 2 to 55 months. In these studies, a total
f 64 women with VPD were treated with imiquimod cream; 56
88%) had an objective clinical response, 43 (67%) had a complete
esponse, and 13 (21%) had a partial response. Only 8 women were
eported to have residual disease after treatment (Luyten et al.,
014; Bertozzi et al., 2009; Gass et al., 2008; Geisler and Manahan,
008; Hatch and Davis, 2008; Cecchi et al., 2010; Challenor et al.,
009; Sendagorta et al., 2010; Tonguc et al., 2011; Hiraldo-Gamero
t al., 2011; Wagner et al., 2012; Baiocchi et al., 2012; Feldmeyer
t al., 2011; Ho and Aw, 2010; Frances et al., 2014; Herranz et al.,
012; Matin et al., 2011; Sanderson et al., 2013; Tanaka et al.,
009; Madnani et al., 2010; Anton et al., 2011; Denehy et al., 2008).
ig. 7 shows a patient from our clinic who has obtained a complete
esponse with topical 5% imiquimod treatment.
A recent observational study examined the effectiveness
f imiquimod cream in 10 patients with non-invasive VPD
Marchitelli et al., 2014). The patients were treated for 5–7 months.
ine patients had a complete response, and one patient had a par-
ial response. Local skin reactions like pain and ulceration were
eported in this cohort without systemic reaction. We  found 16
ublications reporting adverse events in 59 patients (Luyten et al.,
014; Geisler and Manahan, 2008; Hatch and Davis, 2008; Cecchi
t al., 2010; Sendagorta et al., 2010; Tonguc et al., 2011; Hiraldo-
amero et al., 2011; Wagner et al., 2012; Baiocchi et al., 2012;
eldmeyer et al., 2011; Frances et al., 2014; Herranz et al., 2012;
atin et al., 2011). A local adverse reaction, such as pain, ulcera-
ion, or inﬂammation, was reported in 16 patients (Luyten et al.,
014; Wang et al., 2003; Sendagorta et al., 2010; Tonguc et al.,
011; Hiraldo-Gamero et al., 2011; Wagner et al., 2012; Baiocchi
t al., 2012; Feldmeyer et al., 2011; Frances et al., 2014; Herranz
t al., 2012). Five patients reduced the application frequency or
topped for one or more weeks because of these adverse reactions
Wang et al., 2003; Hatch and Davis, 2008; Denehy et al., 2008). In
ost cases, the severity of adverse effects as reported by the patient
as reduced after 4 or 5 weeks of treatment. The recurrence rate
fter treatment with topical imiquimod cream for VPD is unknown.
verall imiquimod seems to be effective, but treatment schedules
iffer greatly between the studies, and there may  be a high risk of
ublication bias.fter 10 weeks (C) of treatment with topical 5% imiquimod cream.
5.2.2. Chemotherapy
Chemotherapy for metastatic EMPD has been reported in one
small study (n = 7) (Oashi et al., 2014). The clinical response of
4 patients after FECOM therapy (combination therapy with 5-
ﬂuorouracil, epirubicin, carboplatin, vincristine, and mitomycin C)
at 4-week intervals showed a partial response according to RECIST
(Response Evaluation Criteria in Solid Tumors). One  case reports
describes a patient with untreated non-invasive VPD who was
treated with radiotherapy and FEC100 (ﬂuorouracil, epirubicin,
and cyclophosphamide) followed by 3 courses of docetaxel for
a lobular breast carcinoma. The VPD clinically disappeared after
chemotherapy, but recurred 2 years later (Tauveron et al.,
2014). Another case report describes the clinical response and
regression of lymph node metastases in a patient with Her2-
Neu-overexpressing VPD after treatment with trastuzumab in
combination with paclitaxel (Hanawa et al., 2011).
One study describes the topical use of bleomycin for 2 weeks
with a resting period of 4–6 weeks in 7 patients with non-invasive
VPD. Four patients had a complete response: three after 2 two-week
courses and one patient needed 4 courses but had a recurrence after
30 months. The other three patients could not be evaluated: one
patient died of intercurrent disease, in one patient therapy was
stopped due to adverse events, and one patient refused further
therapy after a partial response (Watring et al., 1978).
5.2.3. Other topical treatment
Topical corticosteroids are not proven to be effective for VPD.
The current literature includes case reports of women who were
treated with topical corticosteroids without success for an irrita-
tive vulvar skin lesion. Treatment failure led to further examination
of the initially misdiagnosed lesion and resulted in a VPD diagno-
sis (Tonguc et al., 2011; Hiraldo-Gamero et al., 2011; Moller et al.,
2014; O’Connor et al., 2012). Based on clinical experience, topical
application of lidocaine (as a cream or ointment) can relieve pain,
and emollients with zinc oxide can prevent secondary infection
of the lesion. There is no literature available on the symptomatic
treatment of VPD.
5.2.4. Radiotherapy
Radiotherapy has been used as a primary treatment option for
patients with invasive and non-invasive VDP who were not eli-
gible for surgery or who refused surgery, as a treatment option
for patients with recurrence after surgery, and as adjuvant post-
operative therapy (Karam and Dorigo, 2012; Son et al., 2005). Son
et al. described a case series of 3 patients with VPD that includedIn total, 92 patients received radiotherapy, but these were not ana-
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Table 3
Local recurrences after surgical treatment.
Author Number of patients with local recurrence in non-invasive VPD Number of patients with local recurrence in invasive VPD
Black et al. (2007) 17/28 (60.7%) 0
Cai et al. (2013) 7/22 (31.8%) 1/5 (20%)
Crawford et al. (1999) 5/10 (50%) 3/10 (30%)
Creasman et al. (1975) 0/7 (1b) 0/5 (3b)
Curtin et al. (1990) 6/28 (21.4%) 2/5a (2b) (40%)
De Magnis et al. (2013) 13/30 (43.3%) 2/4 (50%)
Fanning et al. (1999) 30/84 (35.7%) 3/12 (25%)
Feuer et al. (1990) 7/14 (50%) 2/3 (1b) (66.7%)
Goldblum and Hart (1997) 4/13 (30.8%) 1/6 (16.7%)
Gregori et al. (1978) 2/13 (15.4%) 0
Jones et al. (1979) 7/32 (21.9%) 4/9 (44.4%)
Lee et al. (1977) 1/5 (20%) 2/7 (28.7%)
Liu et al. (2014) 7/23 (30.4%) 4/8 (50%)
Mendivil et al. (2012) 8/13 (61.5%) 1/3 (33.3%)
Scheistrøen et al. (1997) 6/15 (40%) 2/4 (50%)
Shaco-Levy et al. (2010a, 2010b) 15/46 (32.6%) 3/10 (30%)
Tebes et al. (2002) 4/14 (28.6%) 2/6 (33.3%)
Zollo and Zeitouni (2000) 5/15 (33.3%) 2/6 (33.3%)
Total 144/402 (35.8%) 34/103 (33.0%)
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hPD: vulvar Paget disease.
a 1 patient had metastases in LN.
b Number of patients that died of Paget disease.
ysed by sex or by lesion location (Karam and Dorigo, 2012). The
nvasion depth was not reported. Adjuvant postoperative radio-
herapy was given to 51 patients (55.4%), and 40 patients received
adiotherapy as primary treatment. A dose of 40–50 Gy is recom-
ended for intraepithelial EMPD and 55–65 Gy is recommended
or invasive EMPD or for an associated adenocarcinoma (Besa et al.,
992; Moreno-Arias et al., 2001; Burrows et al., 1995). Long-term
ollow-up shows that recurrence rates after radiotherapy are less
han 20% (Son et al., 2005). Lower doses may  be less effective and
ay  thus have a higher recurrence rate (Brierley and Stockdale,
991). One case report described the use of high-dose-rate super-
cial brachytherapy, also known as plesiotherapy, for VPD. A total
ose of 54 Gy was administered in 3 weekly fractions for 4 weeks.
he patient had a complete response and was free of disease during
8 months of follow-up (Marcos et al., 2012).
.2.5. Photodynamic therapy
Photodynamic therapy (PDT), also known as photochemother-
py, is mainly prescribed by dermatologists (Tidy et al., 1996). A
hotosensitizer such as 5-aminolevulinic acid (5-ALA) or methyl
-amnoplevilunate (MAL) is applied to the lesion. After an incu-
ation period of several hours, the photosensitizer is washed off
nd the lesion is irradiated with visible red light, destroying pro-
iferating tumour cells that have absorbed the photosensitizer (Al
ousef et al., 2011; Raspagliesi et al., 2006). PDT has shown clinical
fﬁcacy for treating superﬁcial cutaneous (pre-) malignancies such
s superﬁcial BCCs, actinic keratosis, and usual VIN (Winters et al.,
008). PDT can be painful and can cause inﬂammation.
Several case reports have evaluated PDT for VPD. Three case
eports of three patients all reported complete responses to PDT
herapy (Al Yousef et al., 2011; Magnano et al., 2013; Zawislak et al.,
004). The reports described using topical antibiotics, tretinoin
.05%, and vitamin E ointment at the lesion site. The patients
eceived 2–3 sessions of 5-ALA or MAL  PDT, and all were free of
isease for the follow-up periods of 3–6 months (Magnano et al.,
013; Zawislak et al., 2004). As side effects, one case reported min-
mal pain and mild erythema for several days after a session. She
ad a partial response and refused surgical treatment. During the
-year follow-up period, there was no invasion of the lesion (Al
ousef et al., 2011). Raspagliesi et al. reported a case series of 7
atients who were treated with PDT; 4 had a complete response, 1
ad a partial response, and 2 patients had stable disease after 1–5months of follow-up. The patients, who were premedicated with
benzodiazepine and NSAIDs, received 3 sessions of MAL  PDT with
a 3-week intervals. Two patients reported having pain for several
days after the treatment (Raspagliesi et al., 2006).
5.2.6. Laser therapy
CO2 laser therapy has been used as a treatment for recurrent VPD
after surgery. One case report described the use of 30-W CO2 laser
therapy for recurrence after multiple extended surgeries. Invasion
was not reported. After the laser treatment, there was  no recur-
rence during the 12 months of follow-up, and the clinical response
was satisfactory (Valentine et al., 1992). Laser therapy has also
been used in combination with PDT and surgery. One case series
describes additional 10 W CO2 laser vaporization after surgery. One
patient had a vulvar adenocarcinoma and was primarily treated
with a radical vulvectomy. The other patients underwent wide local
excision prior to laser therapy. All patients were free of disease
4 months to 4.5 years after treatment (Ewing, 1991). A trial that
included 3 patients with recurrent VPD after surgery subsequently
treated the patients with CO2 laser therapy and 5-ALA PDT. Invasion
was not reported. All patients showed complete response during
12 months of follow-up, although 1 died due to other causes (Fukui
et al., 2009).
5.3. Recurrence rates
Reported local recurrence rates after surgical treatment of VPD
vary from 34–56% (Perez et al., 2014; Fanning et al., 1999). Recur-
rences have also been reported in reconstructive skin grafts and
ﬂaps (Misas et al., 1990; Geisler et al., 1995; Chin et al., 2004).
Table 3 presents an overview of the local recurrence rates of inva-
sive and non-invasive VPD in surgically treated patients (Liu et al.,
2014; Mendivil et al., 2012; De Magnis et al., 2013; Fanning et al.,
1999; Curtin et al., 1990; Lee et al., 1977; Feuer et al., 1990;
Crawford et al., 1999; Tebes et al., 2002; Black et al., 2007; Cai
et al., 2013; Goldblum and Hart, 1997; Gregori et al., 1978; Zollo and
Zeitouni, 2000; Creasman et al., 1975; Jones et al., 1979; Scheistrøen
et al., 1997; Shaco-Levy et al., 2010a, 2010b).Some studies report high recurrence rates regardless of the sur-
gical margin status (Tebes et al., 2002; Black et al., 2007; Bergen
et al., 1989), whereas others found a signiﬁcant correlation between
negative margins and lower recurrence rates (Pierie et al., 2003).
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Table  4
Local recurrences in relation to margin status after surgical treatment of vulvar Paget disease.
Author Number of patients with recurrence in patients with positive
surgical margins
Number of patients with recurrence in patients with negative
surgical margins
Black et al. (2007) 14/20 (70%) 3/8 (37.5%)
Cai et al. (2013)a N/A (38.5%) N/A (18.8%)
Crawford et al. (1999) 7/13 (53.8%) 1/7 (14.3%)
Curtin et al. (1990) 2/6 (33.3%) 3/11 (27.2%)
De Magnis et al. (2013) 10/15 (66.7%) 5/19 (26.3%)
Lee et al. (1977) 0/1 (0%) 3/11 (27.3%)
Liu et al. (2014) 9/15 (60%) 11/31 (35.5%)
Mendivil et al. (2012) 5/11 (45.5%) 4/5 (80%)
Scheistrøen et al. (1997) 1/8 (12.5%) 0/6 (0%)
Shaco-Levy et al. (2010a, 2010b) 20/50 (40%) 3/17 (17.6%)
Tebes et al. (2002) 6/16 (37.5%) 2/7 (28.6%)
Zollo and Zeitouni (2000) 1/6 (16.7%) 5/12 (41.7%)
Totalb 75/161 (46.6%) 40/134 (29.8%)
N/A: not available
a Percentages available only.
b Excluding Cai et al. (2013).
Table 5
Overview of literature reporting patients who  died of extramammary Paget’s disease.
Author Death of disease in patients with
non-invasive EMPD
Death of disease in patients with
microinvasive EMPD (≤1 mm)
Death of disease in patients with
invasive EMPD (> 1) and/or malignancy
Crawford et al. (1999) 0/11 0/7 1/3 (33.3%)
Creasman et al. (1975) 1/10 (10%) N/A 3/5 (60.0%)
Curtin et al. (1990) 0/28 N/A 2/5 (40.0%)
De Magnis et al. (2013) 1/29 (3.4%)a 0/3 0/2b
Feuer et al. (1990) 0/14 NA 1/3 (33.3%)
Ito et al. (2012) 0/18 0/9 5/8 (62.5%)
Jones et al. (2011) 0/38 N/A 2/5 (40.0%)
Mendivil et al. (2012) 0/15 N/A 0/1
Niikura et al. (2006) 0/18 N/A 0/4
Shaco-Levy et al. (2010a, 2010b) 0/46 N/A 1/10 (10%)
Zollo and Zeitouni (2000) 0/19 N/A 1/9 (11.1%)
Total  2/246 (4.9%) 0/19 16/55 (29.1%)
When studies reported cases with invasion ≤1 mm,  they are reported separately in the ‘micro-invasion’ column. Otherwise we assumed cases with invasion ≤1 mm are
classiﬁed as ‘non-invasive’. EMPD: Extramammary Paget disease. N/A: not available.
a Patient that died of disease was also diagnosed with vulvar squamous cell carcinoma.
b Both patients had non-invasive VPD with a vulvar adenocarcinoma.
Table 6
Overview of number of patients with invasive vulvar Paget disease or metastases after treatment for initial non-invasive vulvar Paget disease.
Author N Number of patients with invasive VPD after treatment
for initial non-invasive VPD
Number of patients with metastases after treatment
for  initial non-invasive VPD
Baehrendtz et al. (1994) 28 3 0
Black et al. (2007) 28 1 0
Fanning et al. (1999) 88 1 2
Goldblum and Hart (1997) 19a 1 0
Jones et al. (1979) 39 0 2
Total 202 6 (2.9%) 4 (1.9%)
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a: Total number of patients with non-invasive vulvar Paget disease, VPD: vulvar Pa
a Includes 5 cases of micro-invasion (<1 mm),  the patient with an invasive recurr
able 4 presents an overview of studies that looked at associations
etween recurrence rates and surgical margin status.
Gunn et al. performed a topographical study of VPD in 1980
Gunn and Gallager, 1980). Four specimens from affected vulvas
ere examined, and it was found that the histological presence of
isease extended far beyond the visible lesion. This may  contribute
o the difﬁculties in obtaining a clear margin. Multifocality of the
isease may  also play a part in recognising the extend of the disease.
The type of surgery may  also inﬂuence the recurrence rate. It is
ell known that Paget cells are present in hair follicles and bulbs,
hich can be found deeper into the adipose tissue of the mons pubis
nd labia minora. A skinning vulvectomy may  leave diseased hairsease.
id not have micro-invasive disease at time of ﬁrst diagnosis.
bulbs in the patient, and it is known that laser ablation does not
reach this deep.
There are no data available on the recurrence rates according
to type of VPD, invasion depth or location of the disease. Topical
treatment of VPD is relatively new. Therefore, publications on this
topic do not report sufﬁcient follow up for recurrence rates. Other
treatment modalities have been described in such small sample
sizes, that we  are unable to explore this topic.6. Prognosis and follow up
The overall 5-year survival rate for EMPD in male and female
patients is 75–91% (van der Zwan et al., 2012; Hatta et al., 2008;
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Fig. 8. Flowchart for diagnostic procedures and treatment of patients with VPD.
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to et al., 2012). Patients with invasive Paget disease or with an
ssociated malignancy seem to have signiﬁcantly shorter survival.
s a comparison, the overall 5-year survival rate for vulvar cancer
s reported to be 70% (Lai et al., 2014). Hatta et al. reported on 76
ale and female patients with EMPD and found that 5-year survival
as 100% in the 43 patients with intraepithelial disease and 88.2%
n the patients with microinvasion to the papillary dermis. Eleven
atients with deep invasion did not survive for 5 years (Hatta et al.,
008). Ito et al. reported 30 patients with EMPD and showed that
urvival was 100% for intraepithelial disease and dermal invasion
1 mm.  The 5-year survival rate for patients with dermal invasion
1 mm was 15% (Ito et al., 2012). Table 5 presents an overview of
tudies that report the number of patients who died from EMPD
ased on invasion depth.
Based on the currently available literature, the risk of devel-
ping invasive VPD disease or metastases after treatment for
on-invasive VPD is very low (Table 6). Fanning et al. describe
 patients with extravulvar adenocarcinoma metastases after ini-
ial non-invasive VPD (Fanning et al., 1999). Jones et al. describe 2
atients with metastases, but do not specify the location and histo-
ogical type (Jones et al., 1979). Lesions with nodules, elevated CEA,
eeper invasion depth, and lymph node metastases all correlate
ith a shorter survival time and patients with intraepidermal dis-
ase or microinvasion had signiﬁcantly longer survival time than
atients with invasive EMPD (Hatta et al., 2008; Ito et al., 2012).
. Conclusion and discussion
VPD is a rare skin disease that typically occurs in elderly women.
ts origin remains unclear. Wilkinson’s classiﬁcation is used most
requently to distinguish primary or cutaneous VPD from secondary
PD; the latter is associated with an intestinal or urological malig-
ancy. This separation, however, has been omitted in the 2014
HO classiﬁcation (Crum et al., 2014).
The majority of patients with VPD have non-invasive cutaneous
isease. About 20% of the cases involve invasive VPD, and 5.7% are
ssociated with an underlying vulvar adenocarcinoma. There is no
onsensus on how to distinguish between invasive VPD, VPD with
n underlying associated intestinal/urological malignancy, or vul-
ar adenocarcinoma. Intestinal and urological malignancies might
pread to the vulva in a pagetoid pattern, or Paget cells might cause
n underlying malignancy.
VPD is reported to be associated with other malignancies, in our
eview we found that 3.2% of patients with VPD were reported to
ave been diagnosed with breast cancer, 2.2% with an intestinal
alignancy, 3.9% with an urological malignancy. Based on these
ow ﬁgures, we want to raise the question on the association with
reast, intestinal, and urological malignancies, as there are no stud-
es with age matched control groups. We especially question the
ssociation with concurrent intestinal and urological malignancies,
s they are reported in 1.1% of VPD patients and in 0.7% respec-
ively. Therefore screening for all associated malignancies might be
uperﬂuous. However, as 12% of women will develop breast cancer
uring their lifetime, we do think that all women with VPD should
ndergo mammography, which is an easy and affordable test (UK,
.R., 2014). More research on this topic should be conducted to
upport a screening protocol.
A diagnosis of VPD is conﬁrmed by the presence of Paget cells
n histological examination. Immunohistochemical markers can
e used to differentiate between cutaneous and non-cutaneous
PD, and may  serve as a decision aid in the work-up of patients
ith VPD. Invasive disease should be excluded by accurate histo-
ogical examination or by vulvar mapping. The risk of progression
nto invasive VPD or to metastasis after treatment for non-invasive
PD is low (2.8% and 1.9%, respectively), and the prognosis of non-ncology/Hematology 101 (2016) 60–74 71
invasive VPD is excellent. We  therefore suggest that aggressive
surgical treatment can be avoided in cases of non-invasive VPD.
There seems to be a place for topical treatment, and sometimes
more symptomatic treatment could be considered. Because of the
lack of literature on SLN in VPD, there is no place for SLN proce-
dures in VPD. In case of invasive VPD >1 mm,  standard treatment
of the groin area should consist of uni- or bilateral inguinofemoral
lymphadenectomy.
The risk of recurrence after standard surgical treatment is
high i.e. about 35% for non-invasive VPD. The use of topical
imiquimod cream for the treatment of VPD shows promising results
in small case series, but more research is needed before deﬁnite
conclusions can be drawn. One ongoing study on this topic is
registered at clinicaltrials.gov (NCT00504023); which is currently
not recruiting. Our group has started an observational trial in 20
patients with non-invasive VPD and is currently recruiting patients
(NCT02385188).
Based on the results of this review, we  suggest that the work-
up of VPD patients should include a consultation that addresses
symptoms that could indicate an underlying intestinal or uro-
logical malignancy. A full gynaecological examination should be
performed, including rectal examination. A pap smear can be per-
formed if no recent results are available, and a vulvar biopsy should
be performed to conﬁrm the VPD diagnosis. The immunohisto-
chemical expression pattern can be used to distinguish primary
from secondary VPD. Screening for an associated locoregional
malignancy should be performed in non-cutaneous VPD, or if the
patient has symptoms of a malignancy elsewhere. Even though the
risk of progression into invasive VPD is small, invasion should be
excluded in all patients by vulvar mapping.
Given its aggressive clinical behaviour, invasive VPD should
be treated similarly to vulvar SCC. However, patients with non-
invasive VPD can be treated with a symptomatic approach that
should be individualized. In case of non-cutaneous VPD with an
underlying intestinal or urological malignancy, individualized ther-
apy should be provided. The location and extent of the malignancy
and skin lesion should be taken into account along with symptoms
and patient factors. We  therefore propose a ﬂowchart, based on the
information reported in this review, which is intended to function
as a supportive decision aid (Fig. 8). The treatment of patients with
VPD should be individualized, taking into account the size and loca-
tion of the lesion, the symptoms it causes, and individual patient
factors.
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